60 Degrees Pharmaceuticals Re-Opens ATM Offering for $565K, Continuing Dilutive Capital Raise
SXTP sits 85% above its 52-week low of $1.36 on light trading volume (0.2× avg).
Summary
60 Degrees Pharmaceuticals has re-opened its At-The-Market (ATM) offering for an additional $565,000, continuing a dilutive capital raise after previously halting sales due to reaching a regulatory cap.
Key Events · Financing and Capital Events · SXTP
-
ATM Program Re-Opened
The company has amended its At-The-Market (ATM) offering to allow for the sale of up to an additional $565,000 in common stock. This follows a previous filing on March 11, 2026, which stated the ATM program had reached its regulatory cap and sales were halted.
-
Significant Prior Sales
Through the date of this prospectus supplement, the company has already sold 325,200 shares for aggregate gross proceeds of $980,510.52 under the existing ATM agreement. Additionally, the company has sold $3,684,110 of shares under General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period.
-
Ongoing Dilution for Micro-Cap
The continued and re-opened ATM program indicates an ongoing need for capital, which will result in further dilution for existing shareholders. The $565,000 offering is a substantial amount relative to the company's current market capitalization.
Analysis · SXTP · Life Sciences
This filing re-opens the At-The-Market (ATM) offering for an additional $565,000, following a previous update on March 11, 2026, which indicated the program had reached its regulatory cap and halted sales. The continuous use of the ATM program, especially after a temporary halt, signals an ongoing need for capital for this micro-cap company. The $565,000 offering represents a substantial portion of the company's current market capitalization, indicating significant potential dilution for existing shareholders. The company has already sold $980,510.52 under this ATM agreement and a total of $3,684,110 under Form S-3 General Instruction I.B.6 in the past 12 months, which is a very high amount relative to its current valuation.
At the time of this filing, SXTP was trading at $2.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $1.36 to $17.68. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.